Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 5 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

EXEL News and Commentary

Caps

How do you think EXEL will perform against the market?

Add Stock to CAPS Watchlist

All Players

2,494 Outperform
97 Underperform
 

All-Star Players

638 Outperform
20 Underperform
 

Wall Street

8 Outperform
0 Underperform
 

Top EXEL Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (80.13)
Submitted October 30, 2017

With the stock having retreated from its high, a nice opportunity has been created to go long. The company is carving out a nice share in 2nd line kidney cancer and first-line could win an OK early next year. Liver cancer could be up next. A 2nd… More

BRADYstocks (55.45)
Submitted February 26, 2008

This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.

EXEL VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about EXEL.

Recs

0
Member Avatar Horsemonkey (35.65) Submitted: 1/8/2018 3:08:53 PM : Outperform Start Price: $29.69 EXEL Score: -27.47

I often eschew Biotech at this point in history because the investments hinge on single do or die events like FDA approval. It reminds me of a Red OR Black bet on a craps table. That being said Exelixis caught my attention due to its partnerships with big pharma companies. They already have popular cancer drugs on the market and they received FDA approval on 12/19/17 to expand the drug label on their well performing cancer treatment Cabometyx (to include patients with advanced renal cell carcinoma). This should mean more sales and more exposure, but the investment requires an iron stomach as well as a penchant for risk taking.

Recs

0
Member Avatar ryonjarvis (69.22) Submitted: 12/15/2017 4:25:45 PM : Outperform Start Price: $26.33 EXEL Score: -20.68

Motley Fool Explorer 2018, 1 of 4 Biotech plays.

Recs

0
Member Avatar kkconway (99.60) Submitted: 11/14/2017 2:59:53 PM : Outperform Start Price: $25.04 EXEL Score: -20.60

EXEL has been a Fool favorite for years in spite of doldrum level stock price; that's because the pipeline was slow to show signs of flow-though. NOwadays several new drugs are in Phase III and looking good!

Leaderboard

Find the members with the highest scoring picks in EXEL.

Score Leader

beave35

beave35 (94.11) Score: +1,464.91

The Score Leader is the player with the highest score across all their picks in EXEL.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
Playa14 < 20 12/26/2014 Outperform 5Y $1.27 +1,530.71% +27.84% +1,502.87 0 Comment
beave35 94.11 12/23/2014 Outperform 5Y $1.30 +1,492.95% +28.04% +1,464.91 0 Comment
tomkao < 20 12/15/2014 Outperform 5Y $1.40 +1,379.29% +32.11% +1,347.17 0 Comment
jack0071 70.45 12/3/2014 Outperform 5Y $1.43 +1,348.25% +28.47% +1,319.79 0 Comment
portefeuille 98.80 12/15/2014 Outperform 5Y $1.44 +1,338.19% +31.85% +1,306.34 0 Comment
akoniec 53.61 10/9/2014 Outperform 3Y $1.55 +1,236.13% +35.64% +1,200.48 0 Comment
dcoyne13 40.55 9/16/2014 Outperform 5Y $1.62 +1,178.32% +33.22% +1,145.09 0 Comment
foolerhoff 94.25 1/6/2015 Outperform 5Y $1.64 +1,162.80% +31.78% +1,131.03 0 Comment
new2fool23 37.23 1/5/2015 Outperform 1Y $1.67 +1,140.12% +30.44% +1,109.68 0 Comment
garisonmp3z < 20 1/5/2015 Outperform 5Y $1.67 +1,140.12% +30.44% +1,109.68 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 84.97 7/28/2014 Outperform 3W $4.40 +370.68% +34.64% +336.05 0 Comment
TrackJimCramer 84.97 5/16/2014 Underperform 3W $3.33 +32.13% +5.18% -26.95 7/28/2014 @ $4.40 0 Comment
TrackUltraLong < 20 12/27/2012 Outperform NS $4.57 +353.17% +87.82% +265.35 1 Comment
TrackJGreenblatt 65.35 4/25/2012 Outperform 1Y $4.85 +2.89% +13.39% -10.51 4/15/2013 @ $4.99 1 Comment
TrackStifel 93.47 3/15/2012 Outperform NS $5.42 +282.10% +90.06% +192.04 0 Comment
TrackPoisedTo < 20 1/10/2012 Outperform 5Y $4.89 +323.52% +105.82% +217.70 0 Comment
TrackJimCramer 84.97 4/26/2011 Outperform 3W $12.35 -73.04% +39.51% -112.55 5/16/2014 @ $3.33 0 Comment
TrackIcahn 87.81 2/24/2009 Outperform 1Y $4.69 +341.58% +259.98% +81.59 1 Comment
trackmerriman 69.27 10/16/2008 Outperform NS $4.15 +71.08% +21.49% +49.60 11/18/2009 @ $7.10 0 Comment
TrackCanaccord 61.63 7/8/2008 Outperform NS $5.19 +12.91% +1.82% +11.08 8/6/2008 @ $5.86 0 Comment
TrackSoros 88.42 3/31/2008 Outperform NS $6.95 +197.99% +109.26% +88.72 1 Comment
TrackEveillard 96.21 12/31/2007 Outperform NS $8.63 +139.98% +89.83% +50.15 1 Comment
TrackLazardCapit 83.36 9/14/2007 Outperform NS $10.44 +98.37% +88.92% +9.45 0 Comment

Featured Broker Partners